By intranasal administration for prophylaxis and treatment of allergic rhinitis
• Child 6–11 years: 55 mcg once daily, dose into each nostril, increased if necessary to 110 mcg daily. Reduce dose when controlled. Maximum duration 3 months.
• Over 12 years: 110 mcg once daily, dose into each nostril. Reduce to 55 mcg once daily when controlled.

For the prophylaxis and treatment of allergic and vasomotor rhinitis by intranasal administration
• Over 6 years: 100 mcg twice daily, dose to be administered into each nostril. Maximum of 400 mcg per day. Reduce to 50 mcg twice daily if symptoms are controlled.

Prophylaxis treatment of allergic and perennial rhinitis by nasal spray
• Child 4–11 years: 50 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 50 mcg twice daily.
• Over 12 years: 100 mcg once daily to be administered to each nostril preferably in the morning. Increase if necessary to 100 mcg twice daily. Reduce to 50 mcg once daily when controlled.
Prophylaxis treatment of nasal polyps by nasal spray
• Over 16 years: 200 mcg one to two times per
day administered into each nostril. If no improvement in four to six weeks, consider alternative treatment.

Often available in latex-free versions. Each nebuliser set is supplied with a medication chamber, drive line tubing and a face mask.

Often available in latex-free versions. Each nebuliser set is supplied with a medication chamber, drive line tubing and a face mask.

Latex-free versions are available. Each nebuliser set includes a medication chamber, drive line tubing and a face mask.

Latex-free versions are available. Each nebuliser set includes a medication chamber, drive line tubing and a face mask.

Mucolytic to facilitate expectoration by reducing sputum viscosity.

Nebusal 7%
Inhalation of nebulised solution, 4 ml, up to twice daily.

Non-sedating antihistamine.

• Child 1–5 years: 1.25 mg once daily.
• Child 6–11 years: 2.5 mg once daily.
• Over 12 years: 5 mg once daily.

Long-acting selective beta2 agonist.

Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Nocturnal asthma in patients requiring long-term regular bronchodilator therapy
Prevention of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma only in patients who regularly use an inhaled corticosteroid (not for immediate relief of acute asthma)
By inhalation of aerosol, or by inhalation of powder
• Child 5–11 years: 50 mcg, twice daily.
• Over 12 years: by inhalation, 50 mcg twice daily. Up to 100 mcg twice daily for more severe airway obstruction.

For COPD by inhalation of aerosol, or by inhalation of powder
• Adult: 50 mcg (2 puffs or 1 blister), twice daily.